Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2015, Article ID 279601, 9 pages
http://dx.doi.org/10.1155/2015/279601
Research Article

Improvement in Overall Survival from Extremity Soft Tissue Sarcoma over Twenty Years

1Hofstra North Shore-LIJ School of Medicine, 500 Hofstra University, Hempstead, NY 11549, USA
2Department of Orthopaedics, North Shore Long Island Jewish Medical Center, 270-05 76th Avenue, New Hyde Park, NY 11040, USA
3Biostatistics Unit, Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
4Department of Orthopaedic Surgery, Johns Hopkins University, 601 N. Caroline Street, Baltimore, MD 21287, USA

Received 13 October 2014; Revised 6 January 2015; Accepted 17 February 2015

Academic Editor: Clement Trovik

Copyright © 2015 Andrew J. Jacobs et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Several patient demographic factors, including marital status, have been demonstrated to have prognostic significance for survival in extremity soft tissue sarcoma (ESTS). A study population of 12,546 adult patients diagnosed with ESTS from 1991 to 2010 was identified from the SEER database, a large population-based registry, in order to determine whether overall survival had changed over this recent 20-year period. The study population was divided into three groups by year of diagnosis: 1991–1996, 1997–2003, and 2004–2010. We used the Kaplan-Meier method and Cox proportional hazards regression to assess survival differences between different demographic groups and prognostic clinical characteristics. Over the course of time, the 5-year overall survival rates have increased from 28% in the earliest time period to 62% in the latest . On multivariate analysis, the mortality rate progressively declined from the 1991–1996 group (HR: 3.02, CI: 2.78–3.29) to the 1997–2003 group (HR: 2.21, CI: 2.06–2.37), with the 2004–2010 group having the best overall survival, despite increases in the proportion of patients with tumors greater than 5 cm in size , and those presenting with metastasis .